Wells Fargo analyst Larry Biegelsen initiated coverage of Kestra Medical (KMTS) with an Overweight rating and $28 price target The firm says its survey of 50 cardiologists implies faster wearable cardioverter defibrillator market growth than forecasted and greater share gains for Kestra. The company’s Assure ranked well relative to LifeVest on many key attributes, and 70% of respondents surveyed use or plan to use Assure, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical initiated with a Buy at Stifel
- Kestra Medical initiated with an Overweight at Piper Sandler
- Kestra Medical Technologies: Positioned for Growth with Next-Gen Wearable Cardioverter Defibrillator
- Buy Rating for Kestra Medical Technologies Ltd. Driven by Strong Growth Prospects and Strategic Market Positioning
- Kestra Medical initiated with a Neutral at Goldman Sachs